1. Home
  2. BNTC vs LRMR Comparison

BNTC vs LRMR Comparison

Compare BNTC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

N/A

Current Price

$7.92

Market Cap

315.4M

Sector

Health Care

ML Signal

N/A

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$3.10

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNTC
LRMR
Founded
1995
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.4M
253.5M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BNTC
LRMR
Price
$7.92
$3.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
11
Target Price
★ $23.75
$14.20
AVG Volume (30 Days)
154.2K
★ 1.3M
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 6.67
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$1.92
52 Week High
$14.39
$6.42

Technical Indicators

Market Signals
Indicator
BNTC
LRMR
Relative Strength Index (RSI) 37.62 58.96
Support Level N/A $2.89
Resistance Level $13.87 $4.25
Average True Range (ATR) 0.66 0.30
MACD -0.08 0.09
Stochastic Oscillator 5.18 66.40

Price Performance

Historical Comparison
BNTC
LRMR

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Share on Social Networks: